{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:40:10Z","timestamp":1792608010198,"version":"4.5.0"},"reference-count":240,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00717","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T02:19:10Z","timestamp":1587608350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":112,"title":["Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives"],"prefix":"10.3389","volume":"11","author":[{"given":"Angelika","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"B1","year":"2019","journal-title":"World Population Prospects 2019: Highlights. (ST\/ESA\/SER.A\/423)."},{"key":"B2","first-page":"226","article-title":"Pneumonia in the elderly (geriatric) population.","volume":"11","author":"Janssens","year":"2005","journal-title":"Curr Opin Pulm Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40520-015-0450-0","article-title":"Functional decline and herpes zoster in older people: an interplay of multiple factors.","volume":"27","year":"2015","journal-title":"Aging Clin Exp Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.exger.2017.12.020","article-title":"Inflammation and neutrophil immunosenescence in health and disease: targeted treatments to improve clinical outcomes in the elderly.","volume":"105","author":"Drew","year":"2018","journal-title":"Exp Gerontol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00896","article-title":"Role of dendritic cells in inflammation and loss of tolerance in the elderly.","volume":"8","author":"Agrawal","year":"2017","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10522-018-9754-8","article-title":"The impact of aging on CD4+ T cell responses to influenza infection.","volume":"19","author":"Lorenzo","year":"2018","journal-title":"Biogerontology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.4049\/jimmunol.1500046","article-title":"Naive T cell maintenance and function in human aging.","volume":"194","author":"Goronzy","year":"2015","journal-title":"J Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.exger.2018.01.011","article-title":"Intrinsic and extrinsic contributors to defective CD8+ T cell responses with aging.","volume":"105","author":"Jergovi\u00e6","year":"2018","journal-title":"Exp Gerontol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1042\/CS20171157","article-title":"T follicular helper cell development and functionality in immune ageing.","volume":"132","author":"Gustafson","year":"2018","journal-title":"Clin Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coi.2014.05.008","article-title":"B cell function and influenza vaccine responses in healthy aging and disease.","volume":"29","author":"Frasca","year":"2014","journal-title":"Curr Opin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses.","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/eji.201546178","article-title":"Aging of the immune system: focus on inflammation and vaccination.","volume":"46","author":"Pinti","year":"2016","journal-title":"Eur J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"p. 73","DOI":"10.1159\/000504489","article-title":"Comorbidities in the elderly and their possible influence on vaccine response.","author":"Kwetkat","year":"2020","journal-title":"Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscp Top Gerontol Geriatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"p. 86","DOI":"10.1159\/000504440","article-title":"The impact of obesity and metabolic syndrome on vaccination success.","author":"Frasca","year":"2020","journal-title":"Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscp Top Gerontol Geriatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/COPD.S53590","article-title":"Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease.","volume":"9","author":"Nath","year":"2013","journal-title":"Int J COPD."},{"key":"B16","article-title":"Antibody titers to influenza vaccine wane in patients with heart failure.","volume":"15","author":"Vardeny","year":"","journal-title":"J Card Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","article-title":"Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.exger.2016.02.005","article-title":"Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review.","volume":"77","author":"Weltevrede","year":"2016","journal-title":"Exp Gerontol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/eji.201646762","article-title":"MV. and natural killer cells: shaping the response to vaccination.","volume":"48","author":"Goodier","year":"2018","journal-title":"Eur J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/gerona\/60.5.556","article-title":"An immune risk phenotype, cognitive impairment, and survival in very late life: Impact of allostatic load in Swedish octogenarian and nonagenarian humans.","volume":"60","author":"Wikby","year":"2005","journal-title":"J Gerontol Ser A Biol Sci Med Sci."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-018-0937-3","article-title":"Human cytomegalovirus infection and coronary heart disease: a systematic review.","volume":"15","author":"Du","year":"2018","journal-title":"Virol J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000006007","article-title":"Cohort study on maternal cytomegalovirus seroprevalence and prevalence and clinical manifestations of congenital infection in China.","volume":"96","author":"Wang","year":"2017","journal-title":"Med (U S)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/21645515.2015.1105413","article-title":"Aging, cytomegalovirus (CMV) and influenza vaccine responses.","volume":"12","author":"Frasca","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1016\/S0264-410X(03)00309-8","article-title":"Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-An impact of immunosenescence.","volume":"21","author":"Trzonkowski","year":"2003","journal-title":"Vaccine."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-017-0099-y","article-title":"Long-term maintenance of diphtheria-specific antibodies after booster vaccination is hampered by latent infection with Cytomegalovirus.","volume":"14","author":"Weinberger","year":"2017","journal-title":"Immun Ageing."},{"key":"B26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00430-019-00602-z","article-title":"Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis.","volume":"208","author":"van den Berg","year":"2019","journal-title":"Med Microbiol Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103998","article-title":"Aging and influenza vaccine-induced immunity.","volume":"348","author":"Dugan","year":"2020","journal-title":"Cell Immunol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.1994.03520210045030","article-title":"The efficacy of influenza vaccination in elderly individuals a randomized double-blind placebo-controlled trial from the departments of general practice.","volume":"272","author":"Govaert","year":"1994","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/cid\/cit404","article-title":"Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season.","volume":"57","author":"Kwong","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001269.pub6","article-title":"Vaccines for preventing influenza in healthy adults.","volume":"2","author":"Demicheli","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1086\/648406","article-title":"Efficacy of inactivated split\u2212virus influenza vaccine against culture\u2212confirmed influenza in healthy adults: a prospective.","volume":"200","author":"Beran","year":"2009","journal-title":"Randomized Placebo Controlled Trial J Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6020028","article-title":"Immune history and influenza vaccine effectiveness.","volume":"6","author":"Lewnard","year":"2018","journal-title":"Vaccines."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150700","article-title":"Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes.","volume":"11","author":"Kon","year":"2016","journal-title":"PLoS One."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-199815010-00001","article-title":"Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines A Review and Meta-Analysis of the Literature.","volume":"15","author":"Beyer","year":"1998","journal-title":"Clin Drug Investig."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2649","article-title":"Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.","volume":"340","author":"Waddington","year":"2010","journal-title":"BMJ."},{"key":"B37","first-page":"E28","article-title":"Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden.","volume":"57","author":"Tisa","year":"2016","journal-title":"J Prev Med Hyg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1080\/21645515.2019.1642056","article-title":"Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.","volume":"15","author":"Carlock","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201","article-title":"I-MOVE multicentre case\u2013control study 2010\/11 to 2014\/15: Is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?","volume":"21","author":"Kissling","year":"2016","journal-title":"Eurosurveillance."},{"key":"B40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40266-018-0597-4","article-title":"Influenza vaccination in older adults: recent innovations and practical applications.","volume":"36","author":"Andrew","year":"2019","journal-title":"Drugs and Aging."},{"key":"B41","year":"2020","journal-title":"Impfplan \u00d6sterreich."},{"key":"B42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination.","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14760584.2017.1334554","article-title":"Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.","volume":"16","author":"Belongia","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"B44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/595861","article-title":"Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004\u20132005 season to the 2006\u20132007 season.","volume":"199","author":"Belongia","year":"2009","journal-title":"J Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1016\/j.vaccine.2017.08.034","article-title":"The road to a more effective influenza vaccine: up to date studies and future prospects.","volume":"35","author":"Sano","year":"2017","journal-title":"Vaccine."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.1016\/j.vaccine.2017.09.084","article-title":"Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults.","volume":"35","author":"McElhaney","year":"2017","journal-title":"Vaccine."},{"key":"B47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/21645515.2017.1413518","article-title":"The establishment of surrogates and correlates of protection: useful tools for the licensure of effective influenza vaccines?","volume":"14","author":"Ward","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1016\/j.vaccine.2016.04.023","article-title":"The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations.","volume":"34","author":"Frasca","year":"2016","journal-title":"Vaccine."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1016\/j.vaccine.2010.07.036","article-title":"Clinical and immunologic predictors of influenza illness among vaccinated older adults.","volume":"28","author":"Shahid","year":"2010","journal-title":"Vaccine."},{"key":"B50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.exger.2017.09.015","article-title":"Influenza vaccine-mediated protection in older adults: impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.","volume":"107","author":"Merani","year":"2018","journal-title":"Exp Gerontol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: Different approaches for one goal.","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/j.vaccine.2017.03.092","article-title":"Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis.","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14760584.2018.1471989","article-title":"Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.","volume":"17","author":"Lee","year":"2018","journal-title":"Expert Rev Vaccines."},{"key":"B55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.vaccine.2008.09.092","article-title":"In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.","volume":"27","author":"Co","year":"2009","journal-title":"Vaccine."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/cid\/civ019","article-title":"Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults.","volume":"60","author":"Talbot","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1080\/21645515.2017.1337615","article-title":"Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.","volume":"13","author":"Kumar","year":"2017","journal-title":"Hum Vaccines Immunother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older.","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1034","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial.","author":"Cowling","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1016\/j.vaccine.2015.05.012","article-title":"Recent insights into cutaneous immunization: how to vaccinate via the skin.","volume":"33","author":"Engelke","year":"2015","journal-title":"Vaccine."},{"key":"B61","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/irv.12000","article-title":"Meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events.","volume":"7","author":"Marra","year":"2013","journal-title":"Influenza Other Respi Viruses."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1080\/21645515.2017.1373226","article-title":"A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly and very elderly institutionalized subject.","volume":"13","author":"Nunzi","year":"2017","journal-title":"Hum Vaccines Immunother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40266-015-0303-8","article-title":"Immunogenicity and safety of intradermal influenza vaccine in the elderly: a meta-analysis of randomized controlled trials.","volume":"32","author":"Pileggi","year":"2015","journal-title":"Drugs Aging."},{"key":"B64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/21645515.2017.1328332","article-title":"Immunogenicity, safety and tolerability of intradermal influenza vaccines.","volume":"14","author":"Hung","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1016\/j.vaccine.2011.09.077","article-title":"A systematic review of intradermal influenza vaccines.","volume":"29","author":"Young","year":"2011","journal-title":"Vaccine."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.4161\/hv.25580","article-title":"Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.","volume":"9","author":"Scheifele","year":"2013","journal-title":"Hum Vaccines Immunother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1016\/j.vaccine.2011.05.040","article-title":"Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.","volume":"29","author":"Beyer","year":"2011","journal-title":"Vaccine."},{"key":"B68","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1586\/14760584.2013.811195","article-title":"Influenza virosomes as vaccine adjuvant and carrier system.","volume":"12","author":"Moser","year":"2013","journal-title":"Expert Rev Vaccines."},{"key":"B69","first-page":"1","article-title":"Utility of virosomal adjuvated influenza vaccines: a review of the literature.","volume":"51","author":"Gasparini","year":"2010","journal-title":"J Prev Med Hyg."},{"key":"B70","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0264-410X(97)00087-X","article-title":"Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients.","volume":"15","author":"Conne","year":"1997","journal-title":"Vaccine."},{"key":"B71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis.","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine."},{"key":"B72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.03.014","article-title":"Adjuvant strategies to improve vaccination of the elderly population.","volume":"41","author":"Weinberger","year":"2018","journal-title":"Curr Opin Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/21645515.2015.1011562","article-title":"Immunogenicity of intramuscular MF59- Adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review.","volume":"11","author":"Camilloni","year":"2015","journal-title":"Hum Vaccines Immunother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijid.2019.03.026","article-title":"Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults =65 years of age: Meta-analysis of cumulative clinical experience.","volume":"85","author":"Nicolay","year":"2019","journal-title":"Int J Infect Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"582","DOI":"10.4161\/hv.23239","article-title":"Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.","volume":"9","author":"Orsi","year":"2013","journal-title":"Hum Vaccines Immunother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.vaccine.2019.10.071","article-title":"End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018\/19.","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine."},{"key":"B78","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.vaccine.2019.10.032","article-title":"Protection provided by influenza vaccine against influenza-related hospitalisation in =65 year olds: early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018\/19.","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella\u2212zoster virus\u2013specific cell\u2212mediated immune responses.","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/wnl.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster.","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Postherpetic neuralgia.","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S1386-6532(10)70003-2","article-title":"The impact of varicella zoster virus: chronic pain.","volume":"48","author":"Opstelten","year":"2010","journal-title":"J Clin Virol."},{"key":"B83","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpse zoster and postherpetic neuralgia in older adults.","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy.","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella\u2212zoster virus\u2013specific immune responses in elderly recipients of a herpes zoster vaccine.","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/infdis\/jiy514","article-title":"Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine.","volume":"219","author":"Weinberg","year":"2019","journal-title":"J Infect Dis."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines."},{"key":"B89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines.","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01.","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci Rep."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00663","article-title":"Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21.","volume":"7","author":"Welsby","year":"2017","journal-title":"Front Immunol."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review.","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine."},{"key":"B93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines.","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity.","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older.","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older.","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults =50 years of age.","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"Phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr Opin Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial.","volume":"70","author":"Vink","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study.","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial.","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA J Am Med Assoc."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","article-title":"Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT).","volume":"25","author":"Curran","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B109","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B110","first-page":"S417","article-title":"Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II\/III, randomized clinical trial.","volume":"4","author":"Vink","year":"2017","journal-title":"Open Forum Inf Dis."},{"key":"B111","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/JCM.33.10.2759-2762.1995","article-title":"Six newly recognized types of Streptococcus pneumoniae.","volume":"33","author":"Henrichsen","year":"1995","journal-title":"J Clin Microbiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease.","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B114","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/CMR.00058-15","article-title":"Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective.","volume":"29","author":"Kim","year":"2016","journal-title":"Clin Microbiol Rev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2016.00098","article-title":"Macrolide resistance in Streptococcus pneumoniae.","volume":"6","author":"Schroeder","year":"2016","journal-title":"Front Cell Infect Microbiol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications.","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.micinf.2012.01.012","article-title":"Streptococcus pneumoniae?: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides.","volume":"14","author":"Cornick","year":"2012","journal-title":"Microbes Infect."},{"key":"B118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00004-17","article-title":"Pneumococcal capsular polysaccharide immunity in the elderly.","volume":"24","author":"Adler","year":"2017","journal-title":"Clin Vaccine Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: transmission, colonization and invasion.","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat Rev Microbiol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ismej.2015.99","article-title":"Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients.","volume":"10","author":"De Steenhuijsen Piters","year":"2016","journal-title":"ISME J."},{"key":"B121","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2249.2004.02611.x","article-title":"The role of pneumolysin in pneumococcal pneumonia and meningitis.","volume":"138","author":"Hirst","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1128\/IAI.02225-14","article-title":"Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection.","volume":"82","author":"Pettigrew","year":"2014","journal-title":"Infect Immun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/irv.12398","article-title":"The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis.","volume":"10","author":"Klein","year":"2016","journal-title":"Influenza Other Respi Viruses."},{"key":"B124","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","article-title":"Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.","volume":"13","author":"Henckaerts","year":"2006","journal-title":"Clin Vaccine Immunol."},{"key":"B125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10156-013-0601-1","article-title":"Pneumococcal vaccine and opsonic pneumococcal antibody.","volume":"19","author":"Song","year":"2013","journal-title":"J Infect Chemother."},{"key":"B126","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1016\/j.vaccine.2019.07.005","article-title":"Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up.","volume":"37","author":"MacIntyre","year":"2019","journal-title":"Vaccine."},{"key":"B127","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1128\/IAI.00768-10","article-title":"Older adults have a low capacity to opsonize pneumococci due to low igm antibody response to pneumococcal vaccinations.","volume":"79","author":"Park","year":"2011","journal-title":"Infect Immun."},{"key":"B128","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1128\/CVI.00344-08","article-title":"Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.","volume":"16","author":"Lee","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.vaccine.2012.11.010","article-title":"Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease.","volume":"31","author":"Oishi","year":"2013","journal-title":"Vaccine."},{"key":"B130","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1128\/CVI.00086-12","article-title":"Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20.","volume":"19","author":"Burton","year":"2012","journal-title":"Clin Vaccine Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1086\/520200","article-title":"Reduction in functional antibody activity against streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.","volume":"29","author":"Romero\u2212Steiner","year":"1999","journal-title":"Clin Infect Dis."},{"key":"B132","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.140.11.3793","article-title":"Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies.","volume":"140","author":"Lue","year":"1988","journal-title":"J Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/mi.2014.55","article-title":"Antibody blocks acquisition of bacterial colonization through agglutination.","volume":"8","author":"Roche","year":"2015","journal-title":"Mucosal Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood-2006-01-009282","article-title":"CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.","volume":"108","author":"Kelly","year":"2006","journal-title":"Blood."},{"key":"B135","first-page":"422","article-title":"Maintaining protection agaisnt invasive bacteria with protein-polysaccharide conjugate vaccines.","volume":"426","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.it.2004.11.004","article-title":"Vaccination against encapsulated bacteria in humans: paradoxes.","volume":"26","author":"Weller","year":"2005","journal-title":"Trends Immunol."},{"key":"B137","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1542\/peds.52.5.637","article-title":"Responses of children immunized with the capsular polysaccharde of hemophilus influenzae type b.","volume":"52","author":"Smith","year":"1973","journal-title":"Pediatrics."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.vaccine.2012.06.019","article-title":"Immunization of newborns with bacterial conjugate vaccines.","volume":"31","author":"van den Biggelaar","year":"2013","journal-title":"Vaccine."},{"key":"B139","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study.","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2012.00193","article-title":"Age-related changes in human peripheral blood IGH repertoire following vaccination.","volume":"3","author":"Wu","year":"2012","journal-title":"Front Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4933-2-10","article-title":"Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I Antibody concentrations, avidity and functional activity.","volume":"2","author":"Kolibab","year":"2005","journal-title":"Immun Ageing."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1086\/529142","article-title":"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.","volume":"46","author":"de Roux","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.vaccine.2008.11.098","article-title":"Immunological responses to pneumococcal vaccine in frail older people.","volume":"27","author":"Ridda","year":"2009","journal-title":"Vaccine."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094578","article-title":"A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.","volume":"9","author":"MacIntyre","year":"2014","journal-title":"PLoS One."},{"key":"B146","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55\u201370 years of age.","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B147","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/649839","article-title":"Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle\u2212aged and older adults.","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis."},{"key":"B148","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1016\/j.vaccine.2007.02.062","article-title":"Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.","volume":"25","author":"Jackson","year":"2007","journal-title":"Vaccine."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.vaccine.2019.01.014","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.","volume":"37","author":"Vadlamudi","year":"2019","journal-title":"Vaccine."},{"key":"B150","doi-asserted-by":"publisher","first-page":"404","DOI":"10.14336\/AD.2018.0512","article-title":"Efficacy and safety of the pneumococcal conjugate-13 valent vaccine in adults.","volume":"10","author":"Marra","year":"2019","journal-title":"Aging Dis."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis.","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.vaccine.2016.02.023","article-title":"Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials.","volume":"34","author":"Diao","year":"2016","journal-title":"Vaccine."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.vaccine.2016.06.045","article-title":"The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis.","volume":"34","author":"Kraicer-Melamed","year":"2016","journal-title":"Vaccine."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0146338","article-title":"Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk-A systematic review and meta-analysis.","volume":"11","author":"Schiffner-Rohe","year":"2016","journal-title":"PLoS One."},{"key":"B155","article-title":"Vaccines for preventing pneumococcal infection in adults.","volume":"1","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1086\/315284","article-title":"Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.","volume":"181","author":"Richmond","year":"2000","journal-title":"J Infect Dis."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged =65 years: updated recommendations of the advisory committee on immunization practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B159","doi-asserted-by":"crossref","first-page":"625","DOI":"10.46747\/cfp.6509625","article-title":"Vaccine strategies for prevention of community-acquired pneumonia in Canada.","volume":"65","author":"Kaplan","year":"2019","journal-title":"Candadian Fam Physician."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.29.1800446","article-title":"Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia. Spain, 2017.","volume":"24","author":"Vila-C\u00f3rcoles","year":"2019","journal-title":"Eurosurveillance."},{"key":"B161","first-page":"p. 1","author":"Norris","year":"2017","journal-title":"Vaccination Coverage Among Adults Aged 65 and Over: United States, 2015. NCHS Data Brief, No 281."},{"key":"B162","doi-asserted-by":"publisher","first-page":"728","DOI":"10.15585\/mmwr.mm6627a4","article-title":"Pneumococcal vaccination among medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults.","volume":"66","author":"Black","year":"2017","journal-title":"Morb Mortal Wkly Rep."},{"key":"B163","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies.","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/mmu.2018.00600","article-title":"Novel platforms for the development of a universal inuenza vaccine.","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Immunol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02350","article-title":"Mini-HA is superior to full length hemagglutinin immunization in inducing stem-specific antibodies and protection against group 1 influenza virus challenges in mice.","volume":"9","author":"Van Der Lubbe","year":"2018","journal-title":"Front Immunol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1038\/d41586-019-02751-w","article-title":"Shot for all seasons.","volume":"573","author":"Eisenstein","year":"2019","journal-title":"Nature."},{"key":"B168","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1128\/CVI.00036-10","article-title":"Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.","volume":"17","author":"Lu","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1016\/j.vaccine.2010.09.031","article-title":"GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.","volume":"28","author":"Lu","year":"2010","journal-title":"Vaccine."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.vaccine.2017.01.030","article-title":"17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine.","volume":"35","author":"Campos","year":"2017","journal-title":"Vaccine."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.37015","article-title":"Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination.","volume":"7","author":"Campo","year":"2018","journal-title":"eLife."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002567","article-title":"Trial to evaluate the safety and immunogenicity of inactivated Streptococcus pneumoniae whole-cell vaccine in adults.","author":"Keech","year":"2019","journal-title":"Pediatr Infect Dis J."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/IAI.00846-18","article-title":"A novel, multiple-antigen pneumococcal vaccine protects against lethal Streptococcus pneumoniae challenge.","volume":"87","author":"Chan","year":"2019","journal-title":"Infect Immun."},{"key":"B175","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1164\/rccm.201212-2277OC","article-title":"Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.","volume":"187","author":"Ferreira","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1128\/CVI.00110-08","article-title":"Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.","volume":"15","author":"Simell","year":"2008","journal-title":"Clin Vaccine Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/21645515.2015.1052198","article-title":"Next generation protein based Streptococcus pneumoniae vaccines.","volume":"12","author":"Pichichero","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/14760584.2017.1393335","article-title":"Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.","volume":"16","author":"Pichichero","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines7010009","article-title":"Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens.","volume":"7","author":"Lagousi","year":"2019","journal-title":"Vaccines."},{"key":"B180","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/21645515.2018.1438791","article-title":"IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.","volume":"14","author":"Terauchi","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51356-w","article-title":"LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (\u03bcMT) mice.","volume":"9","author":"Valli","year":"2019","journal-title":"Sci Rep."},{"key":"B183","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines.","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000138","article-title":"Superior immunogenicity of inactivated whole virus h5n1 influenza vaccine is primarily controlled by toll-like receptor signalling.","volume":"4","author":"Geeraedts","year":"2008","journal-title":"PLoS Pathog."},{"key":"B185","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/vim.2017.0022","article-title":"Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate.","volume":"30","author":"Ainai","year":"2017","journal-title":"Viral Immunol."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00646","article-title":"Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization.","volume":"10","author":"Bhide","year":"2019","journal-title":"Front Immunol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/gerona\/gly126","article-title":"Age-associated changes in the respiratory epithelial response to influenza infection.","volume":"73","author":"Chason","year":"2018","journal-title":"J Gerontol Ser A Biol Sci Med Sci."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003274","article-title":"Experimental Human Pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung.","volume":"9","author":"Wright","year":"2013","journal-title":"PLoS Pathog."},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002622","article-title":"Human nasal challenge with streptococcus pneumoniae is immunising in the absence of carriage.","volume":"8","author":"Wright","year":"2012","journal-title":"PLoS Pathog."},{"key":"B190","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1016\/j.vaccine.2005.05.040","article-title":"Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers.","volume":"23","author":"Menzel","year":"2005","journal-title":"Vaccine."},{"key":"B191","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1016\/j.vaccine.2006.05.002","article-title":"Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease.","volume":"24","author":"Meyer","year":"2006","journal-title":"Vaccine."},{"key":"B192","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1016\/j.vaccine.2008.07.082","article-title":"Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.","volume":"26","author":"Gordon","year":"2008","journal-title":"Vaccine."},{"key":"B193","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1016\/j.vaccine.2013.07.049","article-title":"A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine."},{"key":"B194","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14760584.2019.1643719","article-title":"Progress in mucosal immunization for protection against pneumococcal pneumonia.","volume":"18","author":"Gon\u00e7alves","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"B195","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: the challenge of immune changes with aging.","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin Immunol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1473","article-title":"Immunogenicity and safety of a two-dose schedule of whole-virion and AS03 A-adjuvanted 2009 infl uenza A (H1N1) vaccines: a randomised, multicentre, age-stratifi ed, head-to-head trial.","volume":"11","author":"Nicholson","year":"2011","journal-title":"Lancet Infect Dis."},{"key":"B197","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity.","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine."},{"key":"B198","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong Cross-reactive and polyfunctional CD4 T-Cell responses.","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISATM51 as vaccine adjuvant: A systematic review.","volume":"12","author":"Van Doorn","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041451","article-title":"Matrix-mTM adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen.","volume":"7","author":"Reimer","year":"2012","journal-title":"PLoS One."},{"key":"B201","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/cid\/ciu582","article-title":"Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial.","volume":"59","author":"Hung","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B202","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1016\/j.vaccine.2011.05.001","article-title":"Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125. STF2.HA1 SI).","volume":"29","author":"Taylor","year":"2011","journal-title":"Vaccine."},{"key":"B203","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/CVI.00807-13","article-title":"Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02Vin elderly adults.","volume":"21","author":"Pauksens","year":"2014","journal-title":"Clin Vaccine Immunol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.vaccine.2013.10.052","article-title":"Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine."},{"key":"B205","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4110\/in.2015.15.1.9","article-title":"Molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.","volume":"15","author":"Fukuyama","year":"2015","journal-title":"Immune Netw."},{"key":"B206","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/1348-0421.12487","article-title":"Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.","volume":"61","author":"Kataoka","year":"2017","journal-title":"Microbiol Immunol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1128\/IAI.01632-13","article-title":"Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins.","volume":"82","author":"Moffitt","year":"2014","journal-title":"Infect Immun."},{"key":"B208","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejpb.2014.01.002","article-title":"Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.","volume":"87","author":"Vecchi","year":"2014","journal-title":"Eur J Pharm Biopharm."},{"key":"B209","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine."},{"key":"B210","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine."},{"key":"B211","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41590-019-0320-6","article-title":"Human CD8 + T cell cross-reactivity across influenza A.","volume":"20","author":"Koutsakos","year":"2019","journal-title":"B and C viruses. Nat Immunol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-)protective immunity against influenza.","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine."},{"key":"B213","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4 + T cells correlate with disease protection against influenza challenge in humans.","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med."},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00932","article-title":"Imprinting and editing of the human CD4 T cell response to influenza virus.","volume":"10","author":"Nelson","year":"2019","journal-title":"Front Immunol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines.","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B216","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1128\/CVI.00133-17","article-title":"combination of recombinant mycobacterium bovis BCG strains expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis.","volume":"24","author":"Goulart","year":"2017","journal-title":"Clin Vaccine Immunol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/vaccines2010049","article-title":"Development of Streptococcus pneumoniae vaccines using live vectors.","volume":"2","author":"Wang","year":"2014","journal-title":"Vaccines."},{"key":"B218","doi-asserted-by":"publisher","first-page":".e1","DOI":"10.1016\/j.cmi.2016.05.017","article-title":"A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans.","volume":"22","author":"Mubarak","year":"2016","journal-title":"Clin Microbiol Infect."},{"key":"B219","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/mi.2016.41","article-title":"Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection.","volume":"10","author":"Wang","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1128\/IAI.00281-17","article-title":"Th17-mediated cross protection against pneumococcal carriage by vaccination with a variable antigen.","volume":"85","author":"Kuipers","year":"2017","journal-title":"Infect Immun."},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110632","article-title":"Immunosenescence: a systems-level overview of immune cell biology and strategies for improving vaccine responses.","volume":"124","author":"Crooke","year":"2019","journal-title":"Exp Gerontol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5483\/BMBRep.2019.52.1.293","article-title":"Senotherapeutics: emerging strategy for healthy aging and age-related disease.","volume":"52","author":"Kim","year":"2019","journal-title":"BMB Rep."},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly.","volume":"6","author":"Mannick","year":"2014","journal-title":"Sci Transl Med."},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0045-9","article-title":"A roadmap towards personalized immunology.","volume":"4","author":"Delhalle","year":"2018","journal-title":"NPJ Syst Biol Appl."},{"key":"B225","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","article-title":"Personalized vaccinology: a review.","volume":"36","author":"Poland","year":"2018","journal-title":"Vaccine."},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8732191","article-title":"OMIC Technologies and vaccine development: From the identification of vulnerable individuals to the formulation of invulnerable vaccines.","volume":"2019","author":"Cotugno","year":"2019","journal-title":"J Immunol Res."},{"key":"B227","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans.","volume":"12","author":"Nakaya","year":"2011","journal-title":"Nat Immunol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol."},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10369","article-title":"Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination.","volume":"7","author":"Fourati","year":"2016","journal-title":"Nat Commun."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.00305-19","article-title":"The effect of age on the immunogenicity of the live attenuated zoster vaccine is predicted by baseline regulatory T cells and varicella-zoster virus-specific T cell immunity.","volume":"93","author":"Weinberg","year":"2019","journal-title":"J Virol."},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01962","article-title":"An explorative biomarker study for vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults.","volume":"8","author":"van der Heiden","year":"2018","journal-title":"Front Immunol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B233","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2515135518763183","article-title":"Healthcare-associated infections: potential for prevention through vaccination.","volume":"6","author":"McIntosh","year":"2018","journal-title":"Ther Adv Vaccines Immunother."},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00897","article-title":"The elusive anti-candida vaccine: lessons from the past and opportunities for the future.","volume":"9","author":"Wan Tso","year":"2018","journal-title":"Front Immunol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1473-3099(18)30803-X","article-title":"Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.","volume":"19","author":"Frenck","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B236","first-page":"187","article-title":"Impfschutz im alter?: sind \u00f6sterreichische senioren durch Impfungen ausreichend gesch\u00fctzt??","volume":"114","author":"Hainz","year":"2002","journal-title":"Wiener Medizinische Wochenschrift."},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-414","article-title":"Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore.","volume":"14","author":"Hsu","year":"2014","journal-title":"BMC Infect Dis."},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-017-0107-2","article-title":"Vaccines for the elderly: current use and future challenges.","volume":"15","author":"Weinberger","year":"2018","journal-title":"Immun Ageing."},{"key":"B239","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1016\/j.vaccine.2018.10.086","article-title":"Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: a cost-effectiveness analysis.","volume":"36","author":"Shedrawy","year":"2018","journal-title":"Vaccine."},{"key":"B240","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1016\/j.vaccine.2010.03.024","article-title":"Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years.","volume":"28","author":"Weinberger","year":"2010","journal-title":"Vaccine."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:17:45Z","timestamp":1696043865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":240,"alternative-id":["10.3389\/fimmu.2020.00717"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00717","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"article-number":"717"}}